Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

Biotechnology

Life Sciences

Therapeutics

Uvax Bio

Uvax Bio's headquarters in Newark, DE, United States

Ke Li

Kevin O'neill

Pedro Garbes

Matthijs Schoots

Mary Giffear

Katerina Damjanoska

Description

People (1)

Katerina Damjanoska

Jobs